The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).
 
Nizar M. Tannir
Honoraria - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Consulting or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Argos Therapeutics; Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
 
Alice C. Fan
Stock and Other Ownership Interests - Molecular Decisions
Consulting or Advisory Role - verily
Research Funding - Calithera Biosciences
Patents, Royalties, Other Intellectual Property - Stanford Patent has been licensed
 
Richard J. Lee
Consulting or Advisory Role - Valeant/Dendreon
Research Funding - Janssen
 
Bradley Curtis Carthon
Consulting or Advisory Role - Astellas Medivation; Blue Earth Diagnostics; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Othon Iliopoulos
No Relationships to Disclose
 
James Walter Mier
Research Funding - X4 Pharma
Patents, Royalties, Other Intellectual Property - royalties
 
Manish R. Patel
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical
 
Funda Meric-Bernstam
Honoraria - DiaCarta; Sumitomo Group
Consulting or Advisory Role - Clearlight Diagnostics; DarwinHealth; Genentech; GRAIL; Inflection Biosciences; Pieris Pharmaceuticals
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; Effective Pharmaceuticals; Genentech; Jounce Therapeutics; Novartis; Pfizer; PUMA Biotechnology; Taiho Pharmaceutical; ZytoVision
 
Angela DeMichele
Honoraria - Pfizer; Pfizer
Consulting or Advisory Role - Calithera Biosciences; Novartis
Research Funding - Bayer (Inst); Calithera Biosciences (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Millennium (Inst); Pfizer (Inst); Veridex (Inst); Wyeth (Inst)
Travel, Accommodations, Expenses - Calithera Biosciences; Novartis; Pfizer
 
Martin Henner Voss
Honoraria - Novartis
Consulting or Advisory Role - Alexion Pharmaceuticals; Calithera Biosciences; Exelixis; GlaxoSmithKline; Natera; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Genentech/Roche; Pfizer
Travel, Accommodations, Expenses - Novartis; Takeda
 
James J. Harding
No Relationships to Disclose
 
Ramaprasad Srinivasan
Research Funding - Calithera Biosciences (Inst)
 
Geoffrey Shapiro
Consulting or Advisory Role - G1 Therapeutics; Lilly; Pfizer; Roche; Vertex
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly; Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst)
 
Melinda L. Telli
Consulting or Advisory Role - AstraZeneca; PharmaMar; Tesaro; Vertex
Research Funding - Abbvie (Inst); Biomarin (Inst); Biothera (Inst); Calithera Biosciences (Inst); Genentech (Inst); Medivation (Inst); Novartis (Inst); OncoSec (Inst); Pfizer (Inst); PharmaMar (Inst); Tesaro (Inst); Vertex (Inst)
 
Pamela N. Munster
Stock and Other Ownership Interests - OncoSec (I)
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
 
Richard D. Carvajal
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Bristol-Myers Squibb; Castle Biosciences; Genentech/Roche; Iconic Therapeutics; Janssen Oncology; Merck; Novartis
 
Yonchu Jenkins
Employment - Calithera Biosciences; Secom Medical System (I)
Stock and Other Ownership Interests - Calithera Biosciences; Rigel; Secom Medical System (I); Xoma (I)
Consulting or Advisory Role - Rigel; Xoma (I)
Patents, Royalties, Other Intellectual Property - Xoma (I)
 
Samuel H. Whiting
Employment - Calithera Biosciences; Seagen (I)
Stock and Other Ownership Interests - Calithera Biosciences; Seagen (I)
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Todd Michael Bauer
Employment - Sarah Cannon Research Institute; Tennessee Oncology
Consulting or Advisory Role - Ignyta (Inst)
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Peleton (Inst); Pfizer (Inst); Principa Biopharma (Inst); Principa Biopharma (Inst); Roche (Inst); Stemline Therapeutics (Inst)